Ruling out heart failure in primary-care: The cost-benefit of pre-screening using NT-proBNP and QRS width

International Journal of Cardiology

Volumn 130, Issue 3, 2008, Pages 426-437

  Goode, Kevin M ^a   Clark, Andrew L ^a   Cleland, John G F ^a  

^a HULL ROYAL INFIRMARY   (United Kingdom)

Author keywords

Bootstrapping; Cost benefit analysis; Diagnosis; Electrocardiogram; Natriuretic peptides; Primary care

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE;

AGED; ARTICLE; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC VALUE; ELECTROCARDIOGRAM; FEMALE; HEART FAILURE; HEART LEFT VENTRICLE FAILURE; HUMAN; MAJOR CLINICAL STUDY; MALE; PHYSICIAN; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; QRS COMPLEX; SCORING SYSTEM; SCREENING TEST;

AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; COST-BENEFIT ANALYSIS; ELECTROCARDIOGRAPHY; FEMALE; HEALTH CARE COSTS; HEART FAILURE, SYSTOLIC; HUMANS; MALE; MASS SCREENING; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PRIMARY HEALTH CARE; REFERRAL AND CONSULTATION; ROC CURVE; VENTRICULAR DYSFUNCTION, LEFT;

EID: 55749094193     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcard.2007.08.131     Document Type: Article

References (39)

1. McMurray J.J., Petrie M.C., Murdoch D.R., and Davie A.P. Clinical epidemiology of heart failure: public and private health burden. Eur Heart J 19 (1998) 9-16
2. Swedberg K., Cleland J., Dargie H., et al. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): the task force for the diagnosis and treatment of chronic heart failure of the European society of cardiology. Eur Heart J 26 (2005) 1115-1140
3. Wheeldon N.M., MacDonald T.M., Flucker C.J., et al. Echocardiography in chronic heart failure in the community. Q J Med 86 (1993) 17-23
4. Doust J.A. Diagnostic accuracy of natriuretic peptides. Arch Intern Med 165 (2005) 1199
5. Cleland J.G.F., and Goode K. Natriuretic peptides for heart failure. Fashionable? Useful? Necessary?. Eur J Heart Fail 6 (2004) 253-255
6. The National Institute for Clinical Excellence. Management of chronic heart failure in adults in primary and secondary care. NICE Guideline No 5. Available at www nice org uk; 2003.
7. Cowie M.R., Struthers A.D., Wood D.A., et al. Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care. Lancet 350 (1997) 1349-1353
8. Aspromonte N., Feola M., Scardovi A.B., et al. Early diagnosis of congestive heart failure: clinical utility of B-type natriuretic peptide testing associated with Doppler echocardiography. J Cardiovasc Med (Hagerstown) 7 (2006) 406-413
9. Landray M.J., Lehman R., and Arnold I. Measuring brain natriuretic peptide in suspected left ventricular systolic dysfunction in general practice: cross-sectional study. BMJ 320 (2000) 985-986
10. Alehagen U., Lindstedt G., Eriksson H., and Dahlstrom U. Utility of the amino-terminal fragment of pro-brain natriuretic peptide in plasma for the evaluation of cardiac dysfunction in elderly patients in primary health care. Clin Chem 49 (2003) 1337-1346
11. Fuat A., Murphy J.J., Mehrzad A.A., et al. 573 Suspected heart failure in primary care: the utility of N-terminal pro B-type natriuretic peptide (NT proBNP) as a screening test for secondary care referral - a real life study. Eur J Heart Fail Suppl 4 (2005) 128
12. Gustafsson F., Steensgaard-Hansen F., Badskjaer J., et al. Diagnostic and prognostic performance of N-terminal ProBNP in primary care patients with suspected heart failure. J Card Fail 11 (2005) S15-S20
13. Hobbs F.D.R., Davis R.C., Roalfe A.K., et al. Reliability of N-terminal pro-brain natriuretic peptide assay in diagnosis of heart failure: cohort study in representative and high risk community populations. BMJ 324 (2002) 1498A-1500A
14. Lim T.K., Collinson P.O., Celik E., Gaze D., and Senior R. Value of primary care electrocardiography for the prediction of left ventricular systolic dysfunction in patients with suspected heart failure. Int J Cardiol 115 (2006) 73-74
15. Nielsen L.S., Svanegaard J., Klitgaard N.A., and Egeblad H. N-terminal pro-brain natriuretic peptide for discriminating between cardiac and non-cardiac dyspnoea. Eur J Heart Fail 6 (2004) 63-70
16. Wright S.P., Doughty R.N., Pearl A., et al. Plasma amino-terminal pro-brain natriuretic peptide and accuracy of heart-failure diagnosis in primary care: a randomized, controlled trial. J Am Coll Cardiol 42 (2003) 1793-1800
17. Fuat A., Murphy J.J., Hungin A.P., et al. The diagnostic accuracy and utility of a B-type natriuretic peptide test in a community population of patients with suspected heart failure. Br J Gen Pract 56 (2006) 327-333
18. Zaphiriou A., Robb S., Murray-Thomas T., et al. The diagnostic accuracy of plasma BNP and NTproBNP in patients referred from primary care with suspected heart failure: results of the UK natriuretic peptide study. Eur J Heart Fail 7 (2005) 537-541
19. Khan N.K., Goode K.M., Cleland J.G., et al. Prevalence of ECG abnormalities in an international survey of patients with suspected or confirmed heart failure at death or discharge. Eur J Heart Fail 9 (2007) 491-501
20. Kruger S., Filzmaier K., Graf J., et al. QRS prolongation on surface ECG and brain natriuretic peptide as indicators of left ventricular systolic dysfunction. J Intern Med 255 (2004) 206-212
21. Sakhuja R., Chen A.A., Anwaruddin S., Baggish A.L., and Januzzi Jr. J.L. Combined use of amino terminal-pro-brain natriuretic peptide levels and QRS duration to predict left ventricular systolic dysfunction in patients with dyspnea. Am J Cardiol 96 (2005) 263-266
22. Yeo K.T., Wu A.H., Apple F.S., et al. Multicenter evaluation of the Roche NT-proBNP assay and comparison to the Biosite Triage BNP assay. Clin Chim Acta 338 (2003) 107-115
23. Shelton R.J., Clark A.L., Goode K., Rigby A.S., and Cleland J.G. The diagnostic utility of N-terminal pro-B-type natriuretic peptide for the detection of major structural heart disease in patients with atrial fibrillation. Eur Heart J 27 (2006) 2353-2361
24. Chuang M.L., Hibberd M.G., Salton C.J., et al. Importance of imaging method over imaging modality in noninvasive determination of left ventricular volumes and ejection fraction: assessment by two- and three-dimensional echocardiography and magnetic resonance imaging. J Am Coll Cardiol 35 (2000) 477-484
25. Malm S., Frigstad S., Sagberg E., Larsson H., and Skjaerpe T. Accurate and reproducible measurement of left ventricular volume and ejection fraction by contrast echocardiography: a comparison with magnetic resonance imaging. J Am Coll Cardiol 44 (2004) 1030-1035
26. Efron B., and Tibshirani R. Bootstrap methods for standard errors, confidence intervals, and other measures of statistical accuracy. Stat. Sci. 1 (1986) 54-77
27. Collinson P.O. The cost effectiveness of B-Type natriuretic peptide measurement in the primary care setting - a UK perspective. Congest Heart Fail 12 (2006) 103-107
28. Galasko G.I., Barnes S.C., Collinson P., Lahiri A., and Senior R. What is the most cost-effective strategy to screen for left ventricular systolic dysfunction: natriuretic peptides, the electrocardiogram, hand-held echocardiography, traditional echocardiography, or their combination?. Eur Heart J 27 (2005) 193-200
29. Galasko G.I., Lahiri A., Barnes S.C., Collinson P., and Senior R. What is the normal range for N-terminal pro-brain natriuretic peptide? How well does this normal range screen for cardiovascular disease?. Eur Heart J 26 (2005) 2269-2276
30. Fuat A., Murphy J.J., Brennan G., et al. 574 Screening for suspected heart failure with N terminal Pro-B type natriuretic peptide (NT proBNP) in primary care: cost benefit analysis. Eur J Heart Fail Suppl 4 (2005) 128
31. Fuster V., Ryden L.E., Cannom D.S., et al. ACC/AHA/ESC 2006 Guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association task force on practice guidelines and the European society of cardiology committee for practice guidelines (writing committee to revise the 2001 Guidelines for the management of patients with atrial fibrillation): developed in collaboration with the European heart rhythm association and the heart rhythm society. Circulation 114 (2006) e257-e354
32. Raymond I., Groenning B.A., Hildebrandt P.R., et al. The influence of age, sex and other variables on the plasma level of N-terminal pro brain natriuretic peptide in a large sample of the general population. Heart 89 (2003) 745-751
33. Anwaruddin S., Lloyd-Jones D.M., Baggish A., et al. Renal function, congestive heart failure, and amino-terminal pro-brain natriuretic peptide measurement: results from the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) study. J Am Coll Cardiol 47 (2006) 91-97
34. How to diagnose diastolic heart failure. European Study Group on Diastolic Heart Failure. Eur Heart J 1998;19:990-1003.
35. Lubien E., DeMaria A., Krishnaswamy P., Clopton P., Koon J., Kazanegra R., Gardetto N., Wanner E., and Maisel A.S. Utility of B-natriuretic peptide in detecting diastolic dysfunction: comparison with Doppler velocity recordings. Circulation 105 (2002) 595-601
36. Pritchett A.M., Jacobsen S.J., Mahoney D.W., Rodeheffer R.J., Bailey K.R., and Redfield M.M. Left atrial volume as an index of left atrial size: a population-based study. J Am Coll Cardiol 41 (2003) 1036-1043
37. Otto C.M. Textbook of Clinical Echocardiography (3rd Edition). Elsevier Saunders (2004)
38. Maron B.J., McKenna W.J., Danielson G.K., Kappenberger L.J., Kuhn H.J., Seidman C.E., Shah P.M., Spencer III W.H., Spirito P., Ten Cate F.J., and Wigle E.D. American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines. J Am Coll Cardiol 42 (2003) 1687-1713
39. Zoghbi W.A., Enriquez-Sarano M., Foster E., Grayburn P.A., Kraft C.D., Levine R.A., Nihoyannopoulos P., Otto C.M., Quinones M.A., Rakowski H., Stewart W.J., Waggoner A., and Weissman N.J. Recommendations for evaluation of the severity of native valvular regurgitation with two-dimensional and Doppler echocardiography. J Am Soc Echocardiogr 16 (2003) 777-802